Wie hoch ist der Preis für Impel Pharmaceuticals Inc. (IMPL)

Preis für Impel Pharmaceuticals Inc. (IMPL) ist $0.1011

Wie hoch ist die Marktkapitalisierung für Impel Pharmaceuticals Inc. (IMPL)

Marktkapitalisierung für Impel Pharmaceuticals Inc. (IMPL) ist $1.96M

Impel Pharmaceuticals Inc. (IMPL) Aktiensplits

Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.

Jahr	Aktien-Split	Multiplikator	Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.

Jahr

Aktien-Split

Multiplikator

Kumulierter Multiplikator

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Anzahl der Aktiensplits	Kumulierter Multiplikator	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Unternehmen

Anzahl der Aktiensplits

Kumulierter Multiplikator

Land